{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:45:49Z","timestamp":1791942349929,"version":"4.3.4"},"reference-count":55,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Anderson\u2013Fabry disease (AFD) is a rare X-linked lysosomal storage disorder characterized by the accumulation of globotriaosylceramide, leading to multi-organ involvement and significant morbidity. Cardiovascular manifestations, particularly arrhythmias, are common and pose a considerable risk to affected individuals. This overview examines current approaches to arrhythmic risk stratification in AFD, focusing on the identification, assessment, and management of cardiac arrhythmias associated with the disease. We explore advancements in diagnostic techniques, including echocardiography, cardiac MRI, and ambulatory ECG monitoring, to enhance the detection of arrhythmogenic substrate. Furthermore, we discuss the role of genetic and biochemical markers in predicting arrhythmic risk and the implications for personalized treatment strategies. Current therapeutic interventions, including enzyme replacement therapy and antiarrhythmic medications, are reviewed in the context of their efficacy and limitations. Finally, we highlight ongoing research and future directions with the aim of improving arrhythmic risk assessment and management in AFD. This overview underscores the need for a multidisciplinary approach to optimize care and outcomes for patients with AFD.<\/jats:p>","DOI":"10.3390\/diagnostics15020139","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:17:08Z","timestamp":1736399828000},"page":"139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anderson\u2013Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7782-8949","authenticated-orcid":false,"given":"Chiara","family":"Tognola","sequence":"first","affiliation":[{"name":"Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6538-6907","authenticated-orcid":false,"given":"Giacomo","family":"Ruzzenenti","sequence":"additional","affiliation":[{"name":"Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-6264","authenticated-orcid":false,"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[{"name":"Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-5991","authenticated-orcid":false,"given":"Marisa","family":"Varrenti","sequence":"additional","affiliation":[{"name":"Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-1874","authenticated-orcid":false,"given":"Patrizio","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giannattasio","sequence":"additional","affiliation":[{"name":"Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3473-1058","authenticated-orcid":false,"given":"Fabrizio","family":"Guarracini","sequence":"additional","affiliation":[{"name":"Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Averbuch, T., White, J.A., and Fine, N.M. (2023). Anderson-Fabry disease cardiomyopathy: An update on epidemiology, diagnostic approach, management and monitoring strategies. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1152568"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Spinelli, L., Bianco, A., Riccio, E., Pisani, A., and Iaccarino, G. (2024). Cardiac involvement in Anderson-Fabry disease. The role of advanced echocardiography. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1440636"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/heartjnl-2023-322712","article-title":"Disease-specific therapy for the treatment of the cardiovascular manifestations of Fabry disease: A systematic review","volume":"110","author":"Orsborne","year":"2023","journal-title":"Heart"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Iorio, A., Luc\u00e0, F., Pozzi, A., Rao, C.M., Chimenti, C., Di Fusco, S.A., Rossini, R., Caretta, G., Cornara, S., and Giubilato, S. (2024). Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement. Diagnostics, 14.","DOI":"10.3390\/diagnostics14020208"},{"key":"ref_5","first-page":"41","article-title":"Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease","volume":"9","author":"Pisani","year":"2013","journal-title":"JIMD Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc. Imaging."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Azevedo, O., Cordeiro, F., Gago, M.F., Miltenberger-Miltenyi, G., Ferreira, C., Sousa, N., and Cunha, D. (2021). Fabry Disease and the Heart: A Comprehensive Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094434"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"ref_9","first-page":"101152","article-title":"Using artificial intelligence and promoter-level transcriptome analysis to identify a biomarker as a possible prognostic predictor of cardiac complications in male patients with Fabry disease","volume":"41","author":"Kobayashi","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.hfc.2021.07.005","article-title":"Diagnosis and Management of Cardiovascular Involvement in Fabry Disease","volume":"18","author":"Rubino","year":"2022","journal-title":"Heart Fail. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"149127","DOI":"10.1016\/j.gene.2024.149127","article-title":"640-814T>C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect","volume":"936","author":"Zhang","year":"2025","journal-title":"Gene"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sorriento, D., and Iaccarino, G. (2021). The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031331"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e002251","DOI":"10.1136\/openhrt-2023-002251","article-title":"Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation","volume":"10","author":"Valtola","year":"2023","journal-title":"Open Heart."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11886-024-02053-2","article-title":"Arrhythmogenesis in Fabry Disease","volume":"26","author":"Roy","year":"2024","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: A systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Niemann","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","article-title":"Impaired Left Atrial Function in Fabry Disease: A Longitudinal Speckle-Tracking Echocardiography Study","volume":"30","author":"Pichette","year":"2017","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-021-02133-4","article-title":"Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy","volume":"17","author":"Vijapurapu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"Coats","year":"2011","journal-title":"Europace"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"Hollak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","article-title":"A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology","volume":"13","author":"Birket","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Roy, A., O\u2019Shea, C., Dasi, A., Patel, L., Cumberland, M., Nieves, D., Canagarajah, H.S., Thompson, S., Azad, A., and Price, A.M. (2024). Early atrial remodelling drives arrhythmia in Fabry Disease. bioRxiv.","DOI":"10.1101\/2024.08.13.607853"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e007168","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Cardiac Phenotype of Prehypertrophic Fabry Disease","volume":"11","author":"Nordin","year":"2018","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide","volume":"109","author":"Mucci","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e009052","DOI":"10.1161\/JAHA.118.009052","article-title":"Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy","volume":"7","author":"Frustaci","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e002839","DOI":"10.1161\/JAHA.115.002839","article-title":"High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2215\/CJN.06810619","article-title":"Intradialytic Hypotension and Cardiac Arrhythmias in Patients Undergoing Maintenance Hemodialysis: Results from the Monitoring in Dialysis Study","volume":"15","author":"Tumlin","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/CIRCEP.114.002569","article-title":"Pathology and function of conduction tissue in Fabry disease cardiomyopathy","volume":"8","author":"Frustaci","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.120.051400","article-title":"Screening for Fabry Disease in Male Patients with Arrhythmia Requiring a Pacemaker or an Implantable Cardioverter-Defibrillator","volume":"143","author":"Hemelsoet","year":"2021","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/153537020122600903","article-title":"Drug-induced phospholipidosis: Are there functional consequences?","volume":"226","author":"Reasor","year":"2001","journal-title":"Exp. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"132444","DOI":"10.1016\/j.ijcard.2024.132444","article-title":"Ventricular arrhythmias and primary prevention of sudden cardiac death in Anderson-Fabry disease","volume":"415","author":"Piccolo","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1148\/radiol.2019192141","article-title":"Grading Cardiac Risk in Fabry Disease: Is MRI the Answer?","volume":"294","author":"Zimmerman","year":"2020","journal-title":"Radiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"132592","DOI":"10.1016\/j.ijcard.2024.132592","article-title":"Sudden cardiac death risk prediction in Fabry disease: How many strings do we have on our bow?","volume":"418","author":"Monda","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry Disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2022.06.022","article-title":"Validated Model for Prediction of Adverse Cardiac Outcome in Patients with Fabry Disease","volume":"80","author":"Orsborne","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_43","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106967","DOI":"10.1016\/j.ymgme.2022.106967","article-title":"Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry","volume":"138","author":"Hopkin","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","article-title":"Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","volume":"139","author":"Wanner","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","article-title":"Twenty years of the Fabry Outcome Survey (FOS): Insights, achievements, and lessons learned from a global patient registry","volume":"17","author":"Beck","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"Gomaa","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14740338.2021.1891221","article-title":"Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: Aggregate data from two post-authorization safety studies","volume":"20","author":"Tsurumi","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: Evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and Clinical Cardiac Findings in Children with Anderson-Fabry Disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_53","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of F.O.S., Oxford PharmaGenesis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Hughes","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.amjcard.2020.09.035","article-title":"Catheter Ablation for Atrial Fibrillation in Patients with Concurrent Heart Failure","volume":"137","author":"Arora","year":"2020","journal-title":"Am. J. Cardiol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:25:33Z","timestamp":1759919133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15020139"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15020139","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}